Shire's Ornskov on $1 Billion Potential for Dry-Eye Drug(Audio)

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.See omnystudio.com/listener for privacy information.